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1.  ABSTRACT 
Glioblastoma (GBM) is a grade IV primary brain tumor (WHO 2007). Despite last progresses 
in surgery, chemo- and radiotherapy, this brain tumor is still incurable and it always recurs 
(Stupp et al, 2009). It has been hypothesized that its resistance to therapies and its 
recurrence might be due to the existence of a subpopulation of tumor cells called Glioma 
Stem Cells (GSCs )(Galli et al, 2004; Bao et al, 2006). The goal of GBM therapy is the selective 
targeting of GSCs and, among the possibilities, the use of viral vectors has been widely 
investigated (Kroeger et al, 2010). Herpesviruses have been largely studied and modified in 
GBM treatment (Grandi et al, 2009). In this study the capacity of an engineered Bovine 
Herpesvirus type 4 (BoHV-4), named BoHV-4TKdsRED, to selectively kill GSCs has been 
investigated. The vector expresses the HSV-1 Thymidine Kinase and so it can be used with 
Ganciclovir (GCV) in a Suicide Gene Therapy protocol. Its potential role as a vector in GBM 
treatment has already been demonstrated (Redaelli et al, 2012).  
Three different primary cultures of human GSCs (GBM2, GBM4 and GBM5) and the 
corresponding serum-cultured cells (FBS2, FBS4 and FBS5) were used. They have been 
infected with BoHV-4TKdsRED and a combined treatment of the vector with GCV has also 
been tested on GSCs. It has also been analyzed whether signaling pathways of apoptosis or 
autophagy are activated in infected GSCs. To verify the BoHV-4TKdsRED effect on the cells 
counting/killing assays, plaque assays, Western Blot analysis and FACS analysis have been 
done.  
BoHV-4TKdsRED is able to infect GSCs and FBS cells. It can slightly replicate in almost all 
cultures examined and it can kill them in vitro. The combined treatment of the vector with 
GCV leads to an increased mortality in GSCs. Initial signs of autophagy activation were 
detected with the combined treatment in GSCs. 
Study of apoptosis through FACS analysis led to unreliable results. 
Another BoHV-4-derived vector, BoHV-4EGFPΔTK, demonstrated its ability in infecting self-
renewing cells, but without exerting a cytopathic effect. 
According to our results, BoHV-4TKdsRED would be a promising vector to target GSCs, but 
further analysis should be performed to strengthen these data.  
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1. SOMMARIO 
Il Glioblastoma (GBM) è un tumore cerebrale primario di IV grado (WHO 2007). Nonostante 
gli ultimi progressi in chirurgia, chemioterapia e radioterapia, questo tumore al cervello è 
ancora incurabile e recidivante (Stupp et al, 2009). È stato ipotizzato che la sua resistenza 
alle terapie e le recidive potrebbero essere dovute all'esistenza di una sottopopolazione di 
cellule tumorali, denominata cellule staminali di glioma (Glioma Stem Cells - GSC) (Galli et al, 
2004; Bao et al, 2006). L'obiettivo della terapia del GBM è quindi il targeting selettivo delle 
GSCs e, tra le possibilità, l'uso di vettori virali è stata ampiamente studiato (Kroeger et al, 
2010). Gli Herpesvirus sono stati ampiamente studiati e modificati per il trattamento del 
GBM (Grandi et al, 2009). In questo studio è stata valutata la capacità di un vettore 
ingegnerizzato dall’ Herpesvirus Bovino di tipo 4 (BoHV-4), chiamato BoHV-4TKdsRED, di 
uccidere selettivamente le GSC. Il vettore esprime la Timidina Chinasi di HSV-1 e quindi può 
essere utilizzato con il Ganciclovir (GCV) in un protocollo di terapia genica suicida. Il suo 
potenziale ruolo come vettore per il trattamento del GBM è già stato dimostrato (Redaelli et 
al, 2012). 
Sono stati utilizzati tre diverse colture primarie di GSC umane (GBM2, GBM4 e GBM5) e le 
corrispondenti cellule coltivate in siero (FBS2, FBS4 e FBS5). Sono state infettate con BoHV-
4TKdsRED ed è stato testato anche un trattamento combinato del vettore con GCV sulle 
GSCs. È stato anche analizzato qualora vie di segnale di apoptosi o autofagia vengano 
attivate nelle GSCs infettate. Per verificare l'effetto di BoHV-4TKdsRED sono stati compiuti 
saggi di counting/killing, saggi di placca, Western Blot e analisi FACS. 
BoHV-4TKdsRED è in grado di infettare le GSCs e le cellule FBS. Può replicarsi in quasi tutte le 
colture esaminate e le può uccidere in vitro. Il trattamento combinato del vettore col GCV 
porta ad un aumento della mortalità nelle GSCs. Segni iniziali di attivazione dell'autofagia 
sono stati rilevati con il trattamento combinato nelle GSCs. 
Lo studio dell’apoptosi attraverso analisi FACS ha dato risultati non affidabili. 
Un altro vettore derivato da BoHV-4, BoHV-4EGFPΔTK, ha dimostrato la sua capacità di 
infettare le cellule self-renewing, ma senza esercitare un effetto citopatico. 
Secondo i nostri risultati, BoHV-4TKdsRED potrebbe essere un promettente vettore per le 
GSCs, ma ulteriori analisi devono essere effettuate per rafforzare questi dati. 
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2. INTRODUCTION 
2.1 Glioblastoma 
Astrocytic tumors have been classified by the World Health Organization (WHO) in four 
different grades, with an increasing degree of malignancy. On the basis of cytological atypia, 
anaplasia, mitotic activity, microvascular proliferation and necrosis we can distinguish low 
grade gliomas (Grade I Pilocytic astrocytoma; Grade II Diffuse Astrocytoma) and high grade 
gliomas (Grade III Anaplastic astrocytoma; Grade IV Glioblastoma) (Louis et al, 2007). So, 
among the astrocytic tumors, Glioblastoma (GBM) is the most frequent and most malignant 
primary brain tumor in adults, characterized by uncontrolled cellular proliferation, diffuse 
infiltration, necrosis, angiogenesis, resistance to apoptosis and genomic instability (Furnari et 
al, 2007). It has an incidence of 3-4 new cases every 100.000 people per year (WHO, IARC, 
2007).  
In most cases glioblastomas develop de novo as primary glioblastomas characterized by loss 
of heterozygosity (LOH) of chromosome 10q, EGFR amplification, p16INK4a deletion and PTEN 
mutations, but they can also progress from low grade astrocytomas or anaplastic 
astrocytomas in secondary glioblastomas with high frequency of TP53 mutations (Ohgaki et 
al, 2007). 
According to genomic analyses that identified specific abnormalities in some peculiar genes, 
glioblastomas could be classified in 4 different subtypes with different clinical outcomes: 
- Classical: characterized by chromosome 7 amplification paired with chromosome 10 
loss, high level of EGFR amplification, lack of p53 mutations; 
- Mesenchymal: characterized by lower NF1 expression levels, high expression of 
genes in the tumor necrosis factor super family and NF-κB pathway, high expression 
of mesenchymal markers such as CHI3L and MET; 
- Proneural: defined by high levels of PDGFRA expression, point mutations in IDH1, 
TP53 mutations, high expression of OLIG2; 
- Neural: expressing neuron markers such as NEFL, GABRA1 and SYT1 (Verhaak et al, 
2010). 
The complexity of this tumor stays beyond a large amount of genetic mutations. Among 
these, some were identified as prognostic and/or predictive biomarkers. The first of these is 
the chromosome 1p/19q codeletion, often associated with IDH1/IDH2 mutation and 
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exclusive from TP53 mutation and EGFR amplification. Patients with 1p/19q deletion have a 
better prognosis for survival compared with those of equivalent grade that lack the deletion 
(Ahmed et al, 2014). IDH1/IDH2 mutations lead to histone and DNA hypermethylation and 
so in a block of cell differentiation (Lu et al, 2012). In approximately 40% of glioblastomas 
the MGMT (Methyl-Guanine Methyl Transferase) promoter is methylated. This induces low 
expression of MGMT protein, a DNA-repair protein, and this makes cells more sensitive to 
alkylating agents (Hegi et al, 2005). 
The available therapies consist in surgical resection to the extent that is safely achievable, 
followed by radiotherapy and adjuvant chemotherapy with Temozolomide, an alkylating 
agent (Stupp et al, 2005). Despite these combined treatments, the median survival still 
remains around 14.6 months after diagnosis and the average survival rate at five years is 
around 10% (Stupp et al, 2009). Thus GBM is still an incurable disease and the tumor always 
recurs.  
 
2.2 Glioma Stem-Like Cells 
The propagation and the resistance of GBM to therapies are thought to be driven by a 
subpopulation of cells, called Glioma Stem-like Cells (GSCs). Like physiological neural stem 
cells, GSCs display properties of self-renewal and multi-potential differentiation (Ignatova et 
al, 2002). Cancer Stem cells have been first identified in acute myeloid leukemia and breast 
cancer as those cells able to initiate and maintain these neoplasia (Lapidot et al, 1994; 
Bonnet et al, 1997; Al-Hajj et al, 2003). Whether cells like these were present also in brain 
tumors remained a mystery until Singh and colleagues in 2003 identified cells able to 
proliferate, self-renew and differentiate from primary human brain tumors. These cells were 
isolated as described by Reynolds and Weiss in 1992 to identify stem cells in adult 
mammalian striatum (Reynolds et al, 1992). The isolated cells were able to form 
neurosphere-like colonies, self-renew, differentiate in a phenotype identical to the tumor in 
situ and expressed the surface marker CD133, a marker for hematopoietic and neural stem 
cells (Singh et al, 2003). A simultaneous study directed by Galli and colleagues showed the 
presence of multipotent precursors selected from adult human brain tumors. They also 
demonstrated the tumorigenic potential of these cells through transplantation into 
immunosuppressed mice. Histologic analysis of the tumors obtained this way showed a 
pattern very similar to the human one from which the cells were isolated (Galli et al, 2004). 
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Moreover it has been reported that the fraction of tumor cells expressing CD133 increases 
after radiation in gliomas and that GSCs show an increased chemoresistance due to the 
overexpression of drug efflux pumps, such as ABCG2 and ABCA3 transporter proteins (Bao et 
al, 2006; Stopschinski et al, 2012). GSCs also possess efficient DNA-damage repair systems: 
for example, MGMT (Methyl-Guanine Methyl Transferase) a DNA repair gene (Hegi et al, 
2005; Liu et al, 2006). These data lead to the hypothesis that Glioma Stem-like Cells might be 
the cause of GBM recurrence.  
 
Figure 1. The Glioma Stem-like Cell Hypothesis: conventional therapy cannot eradicate the Glioma 
Stem Cells so the tumor recurs. The goal of novel therapies is the specific targeting of Glioma Stem 
Cells (modified from (Dey et al, 2010). 
 
GSCs could be identified by functional criteria such as the ability to self-renew, to be 
multipotent and to be tumorigenic in animal models (Singh et al, 2003; Singh et al, 2004). 
GSCs could also be defined with molecular characteristics that are, to date, not completely 
understood (Bayin et al, 2014). There is not a specific molecular marker for GSCs but only a 
“stemness signature” (Shats et al, 2011).  
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The most famous stem marker, and the most debated one, is CD133, a transmembrane 
protein found in embryonic stem cells, adult neural stem cells and ependymal cells. Isolated 
CD133-positive cells resulted more tumorigenic whether injected into immunodeficient 
animals than CD133-negative cells (Singh et al, 2004), but Beier and colleagues 
demonstrated stem characteristics of CD133-negative cells (Beier et al, 2007). Another 
studied marker is Nestin, an intermediate filament protein in common with neural stem cells 
which expression is increased in GSCs and may be related to an undifferentiated state (Chen 
et al, 2012). Sox2 is a transcription factor highly expressed in GSCs and important for their 
maintenance (Alonso et al, 2011). The expression of Musashi-1, a neural RNA-binding 
protein, resulted higher in high grade gliomas compared to low grade ones (Toda et al, 
2001). Other markers were investigated, but the high heterogeneity of GSCs doesn’t allow to 
identify a universal marker. 
GSCs are also influenced by the environment. Indeed, they may reside in specific niches: the 
perivascular niche of the tumor, where they interact with endothelial cells secreting factors 
useful to maintain their stemness (Calabrese et al, 2007). Moreover, GSCs in this niche 
release Vascular Endothelial Growth Factor (VEGF) contributing to neoangiogenesis (Bao et 
al, 2006). GSCs were also identified in hypoxic regions of the tumor, and in vitro studies 
demonstrated a higher clonogenicity and increased expression of stem markers in GSCs 
cultured under hypoxic conditions (Li et al, 2009; Bar et al, 2010). 
 
2.3 Gene Therapy And Virotherapy Against GBM 
So different strategies can be used to target GSCs and, among these, viruses can be used in 
two different methods. The first one is the virotherapy, where viral vector replication 
induces lysis of the neoplastic cells. This can be achieved through a selective infection of 
cancer cells by the vectors used, sparing the brain parenchyma. The other one is the gene 
therapy, where viral vectors are carriers of transgenes able to correct mutation, to stimulate 
immunity or to activate prodrugs in cancer cells (Dey et al, 2010; Kroeger et al, 2010).  
GBM is a tumor with a peculiar localization and a low tendency to metastasize. These 
characteristics are favorable for the virotherapy because viral vectors can be stereotactically 
injected at the tumor site, avoiding systemic toxic events (Pulkkanen et al, 2005). 
Engineered adenoviruses (Chiocca et al, 2004; Nandi et al, 2009), polioviruses (Goetz et al, 
2010), reoviruses (Kicielinski et al, 2014), retroviruses (Tai et al, 2008), measles virus (Allen et 
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al, 2013) and herpesviruses (Cassady et al, 2010; Wollmann et al, 2012; Ning et al, 2014) 
have been largely studied as oncolytic vectors.  
Among these, Human Herpesvirus type 1 (HSV-1) has been largely used in the latest 25 
years, exploiting its large genome (152kb) which allows an insertion up to 30-50 kb 
transgenes (Bleiziffer et al, 2007). Due to its neurotropism and neurotoxicity it has been 
necessary to delete its neurovirulence genes to permit replication only in dividing tumor 
cells, avoiding infection of the normal brain tissue and lethal encephalitis (Kennedy et al, 
1993; Mineta et al, 1995). Since 1991, when the first oncolytic HSV-1-thymidine kinase-
deficient mutant has been used to kill U87 glioma cells, different generations of oncolytic 
HSV have been engineered (Martuza et al, 1991; Cassady et al, 2010; Wollmann et al, 2012). 
Among these, G207 and G47Δ have also been used to target glioma stem-like cells. G47Δ 
showed a more efficient killing of GSCs than G207, a better reduction of GSCs self renewal 
and in vivo a considerable inhibition of tumor growth in tumor-bearing immunodeficient 
mice (Wakimoto et al, 2009; Sgubin et al, 2012). 
HSV-1 has been also used in protocols of the so called Suicide Gene Therapy (SGT). This type 
of therapy consists in the conversion of prodrugs in toxic metabolites only in those cells that 
express the gene capable to do this conversion (Iwami et al, 2010). Together with cytosine 
deaminase that converts the prodrug 5-fluorocytosine in the toxic metabolite 5-fluorouracil, 
HSV-1 Thymidine kinase gene is the most common gene used in protocols of SGT. HSV-1 TK 
phosphorylates the prodrug Ganciclovir in its triphosphate active compound which inhibits 
DNA synthesis leading to cell death, with 1000-fold greater efficiency than mammalian 
thymidine kinases (Altaner 2008). This method has been tested with different vectors in 
many pilot studies and, to date, in 16 clinical trials with controversial results (Barzon et al, 
2006; Kaufmann et al, 2014).  
In recent years the idea to combine gene therapy or virotherapy with immunotherapy, to 
actively stimulate an anti-tumor immune response, has become increasingly marked (Ning et 
al, 2014). Already in 1999 a pilot study in 4 GBM patients with a retroviral vector expressing 
HSV-1 TK and the cytokine gene IL-2 demonstrated an anti-tumor activity and a subsequent 
clinical trial in an enlarged population of patients (n=12) showed positive responses, in terms 
of safety and regression of tumor masses, in 50% of the cases (Palu et al, 1999; Colombo et 
al, 2005). More recently, an oncolytic HSV-1 (G47Δ) armed with IL-12 has been tested in a 
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new mouse GSC-derived tumor model showing reduction in tumor growth and prolonged 
survival in treated animals (Cheema et al, 2013). 
In the present study a viral vector obtained from the Bovine Herpesvirus type 4 has been 
used. 
 
2.4 Bovine Herpesvirus Type 4 As A Viral Vector In GBM Therapy  
Bovine Herpesvirus type 4 (BoHV-4) belongs to the Gammaherpesvirinae subfamily and to 
the Rhadinovirus genus and has a linear double stranded DNA of approximately 145 kb 
containing a unique central sequence of 110 kb with low G-C content, flanked by 
polyrepetitive DNA (prDNA) of high G-C content and variable size. According to their 
restriction patterns, BoHV-4 strains can be divided in two groups: the Movar 33/63-like and 
the DN 599-like (Bublot et al, 1990). Its genome encodes at least 79 Open Reading Frames 
(ORFs), some of which are homologues to ORFs presents in others Herpesviruses (Palmeira 
et al, 2011). Like other Herpesviruses, BoHV-4 virions are composed of a nucleocapsid 
surrounded by the tegument and enclosed by a lipid envelope forming infectious virus 
particles with a diameter around 200 nm. BoHV-4 envelope has ten glycoproteins, among 
which glycoproteins gB, gH, gL, gM and gN are conserved in all Herpesviruses (Dubuisson et 
al, 1989). Moreover herpesvirus virions are composed also of a variety of host proteins (Lete 
et al, 2012). Glycoproteins are involved in virus attachment, penetration, budding and 
spreading among infected cells. 
Herpesviruses use a core fusion machinery composed of gB and the gH/gL heterodimer to 
enter the cells, but the mechanism is not still completely understood for all Herpesviruses. 
Recently it has been demonstrated that BoHV-4 glycoprotein L is not essential for membrane 
fusion, but its lack causes impaired cell penetration leading to virus growth deficit (Lete et al, 
2012). Moreover BoHV-4 glycoprotein B, one of the most conserved among the herpesvirus 
family, has been shown to be indispensable for virus replication (Franceschi et al, 2013).  
BoHV-4 has not a clear pathogenic role; it has been isolated from samples and cells of 
healthy cattle or cattle with various clinical symptoms such as skin lesions, respiratory 
diseases or metritis (Dubuisson et al, 1989). It establishes persistent infections of the 
monocyte/macrophage lineage in its natural host and in an experimental one, the rabbit 
(Osorio et al, 1982; Osorio et al, 1983). It has been demonstrated that BoHV-4 can replicate 
and causes cytopathic effect (CPE) in a variety of immortalized cell lines and primary cell 
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cultures (Peterson et al, 1988; Donofrio et al, 2002). In recent years a recombinant BoHV-4 
expressing Enhanced Green Fluorescent Protein (EGFP) (BoHV-4EGFPΔTK) has been 
proposed as a gene delivery vector. Donofrio and colleagues demonstrated its ability to 
infect cell lines from different species with or without CPE, viral replication and EGFP 
expression. Further, they proved that it is able to cause a persistent infection in neuronal 
cells (Donofrio et al, 2002). In vivo experiments showed that the intranasal inoculation in 
mice of BoHV-4EGFPΔTK doesn’t cause neuroinvasion or systemic infection and its injection 
in the mouse lateral ventricle carries out EGFP expression in the ependymal cells and in 
GFAP-positive cells of the rostral migratory stream (RMS), without showing any viral 
replication in the mouse brain (Donofrio et al, 2006). 
More recently another vector, BoHV-4-A-TKHSV-1-IRES-dsRed (hereafter referred as BoHV-
4TKdsRED), has been obtained by Prof. Donofrio as follows: the HSV-1-TK Open Reading 
Frame was cut from the pHyTK plasmid vector, subcloned in pIRES2DsRED-Express2 vector 
and linearized with NheI/SmaI restriction enzymes to generate the phCMVie-TKHSV-1-IRES-
dsRed-pA vector. Then the TKHSV-1-IRES-dsRed module was cut and subcloned in the 
pINT2EGFPTK vector (Donofrio et al, 2002), depriving it of the GFP ORF, and obtaining this 
way the pTK-hCMVie-TKHSV-1-IRES-dsRed-pA-pTK construct. The purified gel fragment TK-
hCMVie-TKHSV-1-IRES-dsRed-pA-TK was then electroporated into SW102 bacteria with 
KanaGalK targeted into the BoHV-4-A thymidine kinase locus. After selective growth, the 
BAC-BoHV-4-A was purified and analyzed for TK-hCMVie-TKHSV-1-IRES-dsRed-pA-TK fragment 
integration. After genome characterization, the pBAC-BoHV-4-A- hCMVie-TKHSV-1-IRES-dsRed-
pA plasmid DNA has been electroporated into BEK or BEKcre cells and the recombinant virus 
expanded in MDBK cells. The engineered vector obtained this way expresses HSV-1 TK and 
the Red Fluorescent Protein as a reporter gene. The expression of HSV-1 TK allows the 
infected cells to interact with the prodrug Ganciclovir (GCV) in a protocol of Suicide Gene 
Therapy.  
 
Figure 2. Transgene scheme of BoHV-4TKdsRED (modified from (Redaelli et al, 2012) 
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BoHV-4TKdsRED resulted able to infect immortalized glioma cell lines of rats (F98), mice 
(GL261) and humans (GLI36) and a primary culture of human glioblastoma. Redaelli and 
colleagues demonstrated that the combined treatment with GCV enhances the cytopathic 
effect of the vector and increases apoptotic cell death. In vivo experiments performed on 
mice and rats stereotactically injected with syngeneic glioma cells and subsequently treated 
with BoHV-4TKdsRED and/or GCV demonstrated an increased survival in animals treated 
with BoHV-4TKdsRED in combination with GCV (Redaelli et al, 2012). 
 
2.5 Programmed Cell Death In Cancer 
The aim of an anti-cancer therapy is neoplastic cells death. However, these cells often have 
alterations of signaling pathways of programmed cell death, such as apoptosis and 
autophagy. 
Apoptosis is characterized by biochemical and morphological changes, such as blebbing, 
anoikis and nuclear condensation and fragmentation. Altered expression of some key factors 
of apoptosis pathways may contribute to cancer formation (Ouyang et al, 2012). Anti-
apoptotic proteins are upregulated in GBM, together with downregulation of pro-apoptotic 
proteins (Krakstad et al, 2010). 
Autophagy can act a pro-survival, in cell homeostasis, or a pro-death role, if cells are 
exposed to an excessive stress. It is characterized by the formation of autophagosomes that 
surround cytoplasmic macromolecules and organelles. In early stages of cancer autophagy 
can have a protective role, but can also have a pro-tumor role (Ouyang et al, 2012). The 
autophagic capacity is downregulated in GBM, indeed the reduced expression of autophagic 
proteins positively correlates with the tumor progression (Huang et al, 2010). 
It has been described that HSV-1 infection can induce autophagy or apoptosis in U251 
glioma cell line; moreover autophagy can counteract apoptosis, playing this way a pro-
survival role in infected cells (Tovilovic et al, 2013). γ34.5 gene of HSV-1 blocks autophagy 
during infection through its binding to Beclin 1, so γ34.5-deleted HSV-1 vectors have a more 
pro-autophagic effect in infected cells than wild type virus (Cavignac et al, 2010; Kanai et al, 
2012).  
Sciortino and colleagues showed that BoHV-4 causes apoptotic cell death in a permissive cell 
line (BS/BEK cells) (Sciortino et al, 2000) and recently autophagy induction has been 
demonstrated in MDBK cells after BoHV-4 infection (Montagnaro et al, 2013). 
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3.  AIM OF THE STUDY 
Starting from the published results obtained in glioma cell lines of rats, mice and humans 
infected with BoHV-4TKdsRED (Redaelli et al, 2012), the main aim of the present study is to 
verify whether the vector is able to infect GSCs, to replicate in them and to kill them. 
Further, the present study aims to study BoHV-4TKdsRED effect in combination with the 
prodrug Ganciclovir (GCV), with a particular attention on the possible mechanisms involved. 
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4. MATERIALS AND METHODS  
4.1 Cell Culture  
Human GSCs primary cultures (GBM2, GBM4 and GBM5) derived from human GBM surgical 
specimens have been previously established, following published protocols (Wakimoto et al, 
2009; Sgubin et al, 2012). Surgical specimens were obtained from a 58-years-old man patient 
(GBM2), a 58-years-old woman patient (GBM4) and a 63-years-old woman patient (GBM5). 
Cells have been cultured as spheres in EF20 medium: Neurobasal medium (Life Technologies 
Italia, 21103049; http://www.lifetechnologies.com) supplemented with 3 mmol/l L-
Glutamine (Sigma-Aldrich Chemie GmbH, G6392-1VL; http://www.sigmaaldrich.com), 1X 
B27 supplement (Life Technologies Italia, 17504044), 0.5X N2 supplement (Life Technologies 
Italia, 17502048), 2 µg/ml heparin (Sigma-Aldrich Chemie GmbH, 84020), 0.5X Penicillin, 
Streptomycin/Amphotericin B complex (Euroclone S.p.A, ECM0010D.; 
http://www.euroclone.it), 20 ng/ml recombinant human EGF (R&D System Inc., 236-EG-200; 
http://rndsystems.com) and 20 ng/ml recombinant human FGF2 (Peprotech, 100-18B-50UG; 
http://www.peprotech.com). Cell passaging was performed by chemical dissociation of 
spheres using the NeuroCultTM Chemical Dissociation kit (StemCell Technologies, 05707; 
http://www.stemcell.com).  
Part of the GBM2, GBM4 and GBM5 specimens were digested by trypsin-EDTA 0.05% (Life 
Technologies Italia, 25300-054) and then cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies Italia, 41965039) supplemented with 10% fetal bovine serum 
(FBS) (Life Technologies Italia, 10270-106), 1X Penicillin/Streptomycin Solution (Euroclone 
S.p.A., ECB3001D), 10 µg/ml Tetracycline Hydrochloride (Sigma-Aldrich Chemie GmbH, 
T7660-5G) and 35 ng/ml Mycoplasma Removal Agent (Euroclone S.p.A., ECMC210A) to 
generate adherent cultures (FBS2, FBS4 and FBS5). For these cultures passaging was 
performed by trypsinization.  
The cells were cultured under normoxic conditions (5% CO2, 21% O2) at 37°C in humidified 
incubators. GSCs cultures were maintained until 60 passages before freezing; serum-cultured 
cells were maintained until 30 passages before freezing. 
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4.2 Virus  
BoHV-4EGFPΔTK and BoHV-4TKdsRED were kindly provided by Prof. G. Donofrio (University 
of Parma). 
BoHV-4EGFPΔTK derives from Bovine Herpes Virus type 4 and was obtained by homologous 
recombination of the viral genome with the construct pINT2EGFPTK (Donofrio et al, 2002). 
BoHV-4TKdsRED was obtained by homologous recombination of the viral genome with the 
construct pTK-hCMVie- TKHSV-1-IRES-dsRed-pA (Redaelli et al, 2012). The transgene is 
inserted in the deleted Thymidine Kinase (TK) locus, thus, the engineered vector expresses 
HSV-1 TK and the Red Fluorescent Protein as a reporter gene. The expression of HSV-1 TK 
allows the infected cells to interact with the prodrug Ganciclovir in a protocol of Suicide 
Gene Therapy. 
Human Herpes Simplex Virus type 1 (HSV-1) strain F was kindly provided by Dr. A. Calistri 
(University of Padua). 
 
4.3 Initial Virus Titration  
To assess the initial titer of BoHV-4TKdsRED a classical Plaque Assay was performed on Vero 
Cells, plated at a density of 2*105 cells/well in 6-well plates. Serial dilutions (from 10-6 to 10-
11) of the viral stock were performed in PBS/1%IFBS (Inactivated FBS). 700 μl of each diluted 
sample were used to infect the cells. After 120 minutes of incubation at 37°C, the viral 
inoculum was removed and replaced with DMEM, DMEM/10%FBS and methylcellulose 
(respectively 55%, 20% and 25%); cells were then incubated at 37°C until plaques achieved 
an adequate size (4 days). The medium was then removed and cells were fixed with 
methanol and stained with Giemsa. Plaques were counted and the viral titer was calculated.  
The initial titer of HSV-1 has been performed as described for BoHV-4TKdsRED. 
 
4.4 Cell Growth Curves 
GBM2, GBM4 and GBM5 spheres were dissociated and 2*104 cells/well were plated in 24-
well plates; FBS2, FBS4 and FBS5 confluent cells were trypsinized and plated at the same 
density in 24-well plates. On days 3, 6 and 9 cells were collected and counted on a Burker 
chamber with Trypan Blue. Trypan Blue-excluding cells were counted as viable cells. Each 
condition was performed in triplicate.  
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4.5 Self-Renewal Assay  
GBM2, GBM4 and GBM5 spheres were dissociated with NeuroCultTM Chemical Dissociation 
kit and cells passed through a 40 μm cell strainer (Stem Cell Technology, 27305) to obtain a 
single cell suspension. Cells were then seeded in uncoated 96-wellplates at two dilutions (10 
and 1 cells/well) in 100 μl of EF20 medium. Cells were fed weekly with 100 μl/well of fresh 
medium and spheres counted when a size of 80-100 μm was achieved. Experiments were 
performed three times. 
 
4.6 Virus Yield Assay  
GBM2, GBM4 and GBM5 spheres were dissociated, 2*104 cells/well were plated in 24-well 
plates and infected with BoHV-4TKdsRED at a Multiplicity Of Infection (MOI) 1. At 12, 24, 48 
and 72 hours after infection, cells and supernatants were harvested and processed with 
three freeze/thaw cycles and sonication. The viral titer was determined by Plaque Assay on 
Vero cells as already described. The same experiment was performed with the FBS cultures. 
For GBM5 and FBS5 cells the experiment was extended to 144 and 216 hours after infection. 
Each condition was performed in triplicate.  
 
4.7 Cell Killing Assay  
GBM2, GBM4 and GBM5 spheres were dissociated and plated at a density of 2*104 cells/well 
in 24-well plates and infected with mock or with BoHV-4TKdsRED at MOI 0.5; 3, 6 and 9 days 
after infection cells were trypsinized to dissociate the spheres. Viable Trypan Blue-excluding 
cells were counted on a Burker chamber. The Fraction Affected (Fa) has been calculated 
following the formula: Fa= (1- # alive cells with virus)/average alive mock cells. The same 
experiment was performed with the FBS cultures.  
The same experiment was performed with GBM2, GBM4 and GBM5 cells with HSV-1.  
Each condition was performed in triplicate. 
 
4.8 Suicide Gene Therapy Protocol For Cell Killing Assay  
GBM2, GBM4 and GBM5 spheres were dissociated and plated at a density of 2*104 cells/well 
in 24-well plates. Cells were then infected with mock or BoHV-4TKdsRED at MOI 0.5 and 24 
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hours after infection treated with different concentrations of Ganciclovir GCV (Sigma-Aldrich 
Chemie GmbH, G2536) (0, 10, 50 and 100 μg/ml). After 3, 6 and 9 days cells were trypsinized 
to dissociate the spheres and cells were counted after Trypan Blue on a Burker chamber. 
Each condition was performed in triplicate.  
 
4.9 Western Blots  
GBM2, GBM4, GBM5, FBS2, FBS4 and FBS5 untreated cells were seeded at a density of 5*105 
in Petri dish and after some days collected and centrifuged at 405 rcf for 5 minutes. The 
pellet was resuspended with PBS and centrifuged again. Cells were then resuspended in RIPA 
buffer (Sigma-Aldrich Chemie GmbH, R0278) with protease inhibitors (Roche, 04693116001; 
http://www.roche.com), incubated in ice for 30 minutes and centrifuged at 11800 rcf for 10 
minutes. The supernatant lysates were collected and stored at -80°C. Protein concentrations 
were determined by BCA Protein Assay (Micro BCA Protein Assay kit, Thermo Scientific 
Pierce, 23235; http://www.piercenet.com). Proteins were separated on a 7.5%, 10% or 12% 
SDS-PolyAcrylamide gels, transferred to nitrocellulose membrane (GE HealthCare, RPN303D; 
http://www.gelifesciences.com). Blocking was performed with 5% nonfat dry milk (Bio-Rad, 
170-6404; http://www.bio-rad.com) or Bovine Serum Albumin (BSA) (Sigma-Aldrich Chemie 
GmbH, A9647) in Tris-Buffered Saline and Tween 20 (TBST) 0.1% for 45 minutes at room 
temperature. Membranes were then incubated overnight with primary antibodies at 4°C. 
The next day membranes were washed tree times with TBST 0.1% (10 minutes each time). 
Membranes were then incubated with the corresponding secondary peroxidase-conjugated 
antibody for 1 hour at room temperature and washed four times with TBST 0.1% (10 
minutes each time). Proteins were then visualized with ECL Western blotting detection kit 
(GE HealthCare, RPN2106) on Kodak films (Sigma-Aldrich Chemie GmbH, Z370371-50EA).  
The primary antibodies used were as follows: 1:5000 goat anti-Nestin (SCBT, sc21247); 
1:1000 rabbit anti-Sox2 (Cell Signaling, 3579); 1:1000 mouse anti-α-tubulin (Sigma-Aldrich 
Chemie GmbH, T5168); 1:1000 mouse anti-GFAP (Sigma-Aldrich Chemie GmbH, G3893); 
1:500 rabbit anti-VEGF (SCBT, sc152); 1:1000 rabbit anti-βIII-tubulin (Covance, MRB-435P)  
The secondary HRP-conjugated antibodies were diluted in 5% nonfat dry milk in TBST 0.1% 
as follows: 1:2000 anti-rabbit IgG (GE HealthCare, RPN4301), anti-mouse IgG (GE HealthCare, 
RPN4201) and anti-goat IgG (Chemicon, API06P).  
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GBM2 cells were seeded at a density of 5*105 cells/well in a 6-wellplate and the day after 
infected with mock or BoHV-4TKdsRED at MOI 1. After 24 hours cells were treated or not 
with GCV at a concentration of 50 μg/ml and the day after cells were collected and proteins 
extracted as described above.   
GBM2 and GBM5 cells were seeded as already described and the day after treated with 
BoHV-4TKdsRED at MOI 1, Rapamycin (SCBT, sc3504) 1 µM or 2 µl of DMSO. After 24 hours 
cells were treated or not with GCV 50 μg/ml. Cells were collected at different time points: 
24, 48 and 72 hours post BoHV-4TKdsRED infection; 24 and 48 hours post GCV treatment; 
24, 48 and 72 hours post Rapamycin treatment. 
Western Blots were performed as depicted above and additional primary antibodies were 
used: 1:1000 rabbit anti-p62 (Sigma-Aldrich Chemie GmbH, P0067); 1:1000 rabbit anti-LC3 
(Sigma-Aldrich Chemie GmbH, L7543). 
 
4.10 FACS Analysis  
GBM2, GBM5 and FBS5 cells were seeded at a density of 2.5*105 cells/well in a 6-wellplate 
and the day after treated with mock or BoHV-4TKdsRED at MOI 1, with Paclitaxel (Sigma-
Aldrich Chemie GmbH, T7191-1MG) 100 nM or 2 µl of DMSO. 24 hours later cells were 
treated or not with GCV 50 μg/ml. GBM2 and GBM5 cells were collected 72 hours after 
BoHV-4TKdsRED infection, Paclitaxel or DMSO treatment, pelleted and dissociated with 100 
µl of Versene. FBS5 cells were washed once with PBS and trypsinized. Versene or trypsin 
were inactivated with DMEM 10% FBS. Cells were centrifuged, pellets washed twice with 1 
ml of PBS and resuspended in Annexin V Binding Buffer (BD PharmingenTM, 556454; 
http://www.bdbiosciences.com). Cells were stained with FITC-Annexin V (BD PharmingenTM, 
556420) and Propidium Iodide (Sigma-Aldrich Chemie GmbH, P4170) following the 
manufacturer protocol. Samples were then analyzed using a FACScaliburTM (BD Biosciences; 
http://www.bdbiosciences.com). 
 
4.11 BoHV-4EGFPΔTK Infection Of GSCs 
2.5*104 GBM5 cells were plated and the day after infected with BoHV-4EGFPΔTK at MOI 0.2. 
The infection was monitored through EGFP expression under epifluorescence microscope 
(Leica DMIL LED). After 7 days of infection cells were dissociated with NeuroCultTM Chemical 
Dissociation kit and plated 1 cell/well in uncoated 96-wellplate. Cells were fed weekly with 
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100 μl/well of fresh medium until spheres formation. Spheres were collected, mechanically 
dissociated and separately transferred in T25 flasks. Cells were then monitored until 60 days 
after infection. 
 
4.12 Statistical Analysis 
Differences in cell growth, killing assay and suicide gene therapy protocol were compared 
using a two-tailed unpaired t-test. p values <0.5 and p<0.01 were considered significant 
using GraphPad (GraphPad Software; http://www.graphpad.com) and Excel (Microsoft; 
http://www.microsoft.com).  
 5. RESULTS 
5.1. Cell Characterization
5.1.1 Cell Growth 
The use of primary cultures implicates the necessity to study how the cells grow. To 
determine the GSCs growth, GBM2, GBM4 and GBM5 cells were dissociated, 2
were plated and counted at day 3, 6 and 9 after plating. As expected each GSCs culture 
showed different growth rates. 
In 9 days GBM2 cells increased five
Significant differences have been calculated between day 0
and p=0.0126 respectively; unpaired t
GBM4 cells increased four
differences between day 3
unpaired t-test; n=9). 
The number of GBM5 cells at day 9 was almost seven
(Figure 3C). In this case significant differences have been calculated between each time point 
(p=0.0062, p=0.0003 and p=0.0391 respectively; unpaired t
 
Figure 3. GBM2 (A), GBM4 (B) and GBM5 (C) growth curves. (*p<0.05; ** p<0.001; mean ± S
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-fold compared to their initial number (Figure 3A). 
-day 3 and day 3
-test; n=9).  
-fold their number after 9 days (Figure 3B), showing significant 
-day 6 and day 6-day 9 (p=0.0132 and p=0.0056 respectively; 
-fold compared to their initial one
-test; n=9). 
*104cells/well 
-day 6 (p=0.0156 
 
 
D) 
 The same experiment was performed with FBS2, FBS4 and FBS5 cells. FBS2 cells reached 
after 9 days a cell number five
differences between day 0
unpaired t-test; n=6). 
FBS4 cells achieved at day 9 a cell number twenty
at day 0 (Figure 4B). A significant difference have been calculated between day 0
(p=0.0215; unpaired t-test; n=3).
FBS5 cells reached at day 9 a cell number twenty
significant differences calculated between each time point (p=0.02, p=0.012 and p=0.0033 
respectively; unpaired t-test; n=6).
Figure 4. FBS2 (A), FBS4 (B) and FBS5 (C) growth c
 
From these results, it is possible to infer that GBM2, GBM4 and GBM5 cells have a gradual 
time-dependent growth. Except for FBS2 cells, with a growth rate comparable to GBM2 cells, 
FBS4 and FBS5 cells showed a huge 
rapid replication especially in the first 3 days.
These results are consistent with the published data, showing that GSCs have a low 
replication rate (Bao et al, 2006
19 
-fold the initial cell number (Figure 4A), with significant 
- day 6 and day 0-day 9 (p=0.0136 and p=0.0302 respe
-fold higher compared to the cell number 
 
-fold their initial one (figure 4C), with 
 
urves. (*p<0.05; ** p<0.001; mean ± SD)
growth, faster than their stem counterpart, with a very 
 
). 
ctively; 
-day 3 
 
 
 5.1.2 Self-Renewal Assay
One of the peculiar characteristics of GSCs is their self
GBM2, GBM4 and GBM5 cells to form spheres has been tested. Single
plated at clonogenic densities, 1 cell/well and 10 cell/well, in 100
counted when a diameter of 80
Almost 20% of GBM2 cells can sel
(Figure 5B); GBM5 cells showed the highest percentage of self renewing cells among our 
cultures, 28% of cells can form spheres (Figure 5C).
 
Figure 5. Percentage of cells forming spheres in GBM2 (A), GBM4 (B) and GBM5 (C). (mean ± SD)
 
5.1.3 Markers Expression
The expression of stem markers as Nestin and Sox2 in GSCs is well described in literature 
(Alonso et al, 2011; Chen 
expression of Nestin, Sox2, the neuronal marker βIII
protein GFAP. 
Nestin was expressed in GBM2, GBM4 and GBM5 cells and very low expressed in FBS2 and 
FBS4 cells; Sox2 was expressed in GBM2, GBM4 and GBM5 cells but not in FBS cultures; βIII
tubulin was expressed in GBM2, GBM4, FBS2 and FBS4 cells, but not in GBM5 and FBS
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-renewal capability, so the ability of 
-
 
-100 µm was reached. 
f renew (Figure 5A); in GBM4 cells 12% can form spheres 
 
 
et al, 2012). In order to characterize our cultures we tested the 
-tubulin and the glial fibrillary acidic 
cell suspensions were 
µl and spheres were 
 
 
-
5 cells; 
 GFAP was expressed in GBM2 cells and a very high expression has been observed in GBM4 
cells. α-tubulin was used as loading control (Figure 6).
 
Figure 6. Western Blot performed on GBM2, GBM4, GBM5, FBS2, FBS4 and FBS5 lysates showing cell 
markers expression.  The lowest band in α
GFAP. 
 
5.2. BoHV-4TKdsRED 
2.1 Initial Virus Titration
After Plaque Assay on Vero cells with serial dilutions of BoHV
counted and the titer of the viral stock obtained was 3*10
The titer of the viral stock of HSV
 
5.2.2 BoHV-4TKdsRED 
The replication ability of BoHV
of GBM2, GBM4 and GBM5 cells supernatants collected 12, 24, 48 and 72 hours after 
infection at MOI 1. 
BoHV-4TKdsRED can weakly replicate in GBM2 cells (Figure 7A); the viral titer calculated 72 
hours after infection was sl
hours after infection 4.5*10
replicate (Figure 7B); the calculated viral titer 72 hours after infection was 2.55*10
In GBM5 cells BoHV-4TKdsRED can’t replicate within 72 hours of infection; the calculated 
viral titer at this time point (5.71*10
classical shape of a viral replication was observed, the experiment was extended ti
216 hours after infection, to test whether the viral replication needs more time in these 
cells. The viral titers obtained at these time points was 1.41*10
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-tubulin in the right panel is due to incomplete stripping of 
Infection 
 
-4TKdsRED, plaques were 
8pfu/ml. 
-1 obtained in the same way was 3*10
Replication In GSCs And FBS Cultures 
-4TKdsRED has been analyzed through viral titer quantification 
ightly higher compared to the initial input (input 4*10
5pfu/ml). Also in GBM4 cells BoHV-4TKdsRED can slightly 
3pfu/ml) was lower than the initial input. Since the 
5pfu/ml and 1.17*10
 
7pfu/ml. 
4pfu/ml; 72 
5pfu/ml. 
ll 144 and 
5pfu/ml 
 respectively at 144 and 216 hours after infection (Figure 7C). 
more slowly in GBM5 cells than in our others GSCs cultures.
Figure 7. Replication curve of BoHV
 
The same experiment has been performed on FBS cultures. BoHV
replicate in FBS2 cells (Figure 8A); after 72 hours of infection the viral titer calculated was 
1.72*105pfu/ml. The virus can replicate in FBS4 cells (Figure 8B); the viral titer 72 hours after 
infection reached 1.9*107
replicate in FBS5 cells within 72 hours (Figure 8C). The calculated viral titer at this time point 
was 2.52*104pfu/ml, so the experiment was extended, but even 144 and 216 hours after 
infection the viral titer resulted lower
1.22*104pfu/ml; 216 hours after infection 3.1*10
before completing the viral replication cycle.
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-4TKdsRED in GBM2 (A), GBM4 (B) and GBM5 (C). (mean ± SD)
-4TKdsRED ca
pfu/ml. As in their stem counterpart BoHV
 than the initial input (144 hours after infection 
3pfu/ml). Probably the virus kills the cells 
 
-4TKdsRED replicates 
 
 
n slightly 
-4TKdsRED cannot 
 Figure 8. Replication curve of BoHV
 
5.2.3 Killing Effect Of 
One of the main aim of the project is the investigation about the killing ability of BoHV
4TKdsRED on GSCs. To check this ability, GBM2, GBM4 and GBM5 cells were plated at a 
density of 2*104cells/well and the day after were infected with mock or BoHV
(MOI 0.5). After 3, 6 and 9 days of infection cells were counted. The Fraction affected (Fa) 
has been calculated as a ratio between the number of cells infected in each well and the 
average number of mock cells in 3 wells for each time point, using the following formula: Fa= 
(1 - #alive cells with BoHV-4TKdsRED) / average alive mock cells.
GBM2 cells were killed by BoHV
were affected with a significant difference between day 6
n=6). 
At day 9 87% of GBM4 cells were affected (Figure 9B). Significant differences have been
calculated between day 3
unpaired t-test; n=3). 
BoHV-4TKdsRED can kill also GBM5 cells (Figure 9C). At day 9 the percentage of cells affected 
was 67%, with a significant difference between day 3
23 
-4TKdsRED in FBS2 (A), FBS4 (B) and FBS5 (C). (mean ± SD)
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-4TKdsRED (Figure 9A): 9 days after infection 70% of cells 
-day 9 (p=0.0253; unpaired t
-day 6 and day 6-day 9 (p=0.0134 and 0.0013 respectively; 
-day 6 (p=0.0083; unpaired t
 
 
-
-4TKdsRED 
-test; 
 
-test; n=6). 
 The same experiment has been performed with our FBS cultures. FBS2 cells were almost 
completely killed by BoHV-
significant difference between day 3
Also 98% of FBS4 cells were affected after 9 days of infection (Figure 9E) and significant 
differences have been calculated between day 3
p=0.0013 respectively; unpaired t
FBS5 cells were less sensitive to BoHV
after infection 72% of cells were affected with a significant difference between day 6
(p=0.0032; unpaired t-test; n=3).
Figure 9. Fraction affected of GBM
and 9 days after infection with BoHV
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4TKdsRED after 9 days (98% of cells affected) (Figure 9D), with a 
-day 6 (p=0.0039; unpaired t-test; n=3).
-day 6 and day 6-
-test, n=3). 
-4TKdsRED than other FBS cultures (Figure 9F). 9 days 
 
2 (A), GBM4 (B), GBM5 (C), FBS2 (D), FBS4 (E) and FBS5 (F) at 3, 6 
-4TKdsRED at MOI 0.5. (*p<0.05; ** p<0.001; mean ± SD)
 
day 9 (p<0.0001 and 
-day 9 
 
 
 
 In order to compare the killing ability of BoHV
1 wild type on GSCs on our GSCs cultures, GBM2, GBM4 and GBM5 cells were treated with 
HSV-1 wild type at the same MOI 0.5 used for BoHV
As expected GSCs were more sensitive to HSV
infection. 9 days after infec
Significant differences have been calculated between day 3
in GBM2, p=0.0034 in GBM4 and p=0.0191 in GBM5 respectively; unpaired t
Figure 10. Fraction affected of GBM2 (A), GBM4 (B) and GBM5 (C) at 3, 6 and 9 days after infection 
with HSV-1 wild-type (HSV1wt) at MOI 0.5. (*p<0.05; mean ± SD)
  
5.2.4 Suicide Gene Therapy Protocol In 
BoHV-4TKdsRED has been engineered to expres
cells sensitive to GCV (Redaelli
different concentrations of GCV (10, 50 and 100 µg/ml) have been tested in our GSCs 
cultures. GBM2, GBM4 and GBM5 cells were plated at a density of 2*10
day after treated or not with GCV. Cells were then counted after 3, 6 and 9 days and the 
fraction affected calculated as previously described.
25 
-4TKdsRED with the well
-4TKdsRED. 
-1 wild type infection than to BoHV
tion GSCs were almost completely killed by the virus (Figure 10). 
-day 6 in each culture (p=0.0343 
 
GSCs And FBS Cultures 
s HSV-1 TK, in order to make the infected 
 et al, 2012). To evaluate the cytotoxic effect of the drug, 
 
-known effect of HSV-
-4TKdsRED 
-test; n=3).  
 
4 cells/well and the 
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In GBM2 cells GCV had a time- and dose-dependent increasing cytotoxicity (Figure 11A). 
Significant differences have been calculated between GCV 10 µg/ml-GCV 100 µg/ml and GCV 
50 µg/ml-GCV 100 µg/ml at day 9  (p=0.02951 and p=0.0485 respectively; unpaired t-test; 
n=3). 
The same effect has been observed in GBM4 cells (Figure 11B), with significant differences at 
day 3 between GCV 10 µg/ml-GCV 50 µg/ml (p=0.0152; unpaired t-test) and at day 9 
between GCV 10 µg/ml-GCV 100 µg/ml (p=0.0023; unpaired t-test; n=3). 
In GBM5 cells this effect could not be seen (Figure 11C). Significant differences have been 
calculated at day 3 between GCV 10 µg/ml-GCV 50 µg/ml (p=0.0377; unpaired t-test) and at 
day 9 GCV 10 µg/ml-GCV 100 µg/ml (p=0.0023; unpaired t-test; n=3), but the fraction 
affected remained almost unchanged between the different time points considered. This 
result can be due to a higher percentage of self-renewing cells in GBM5. 
To test the combined treatment of virus and prodrug, GBM2, GBM4 and GBM5 cells were 
plated as already described, the day after infected with mock or BoHV-4TKdsRED at MOI 0.5 
and after 24 hours treated using the range of GCV concentrations tested. The cell fraction 
affected has been calculated as already described. 
The use of GCV increases the killing effect of BoHV-4TKdsRED in a time- and dose-dependent 
manner in each culture examined.  
In GBM2, at day 3 and at day 6, the fraction affected of cells treated only with BoHV-
4TKdsRED was significantly lower compared to the fraction affected with BoHV-4TKdsRED 
plus GCV 50 µg/ml and GCV 100 µg/ml (at day 3 p=0.034 and p=0.037 respectively; at day 6 
p=0.037 and p=0.008 respectively; unpaired t-test; n=6) (Figure 11D). 
In GBM4 cells a significant difference has been calculated at day 3 between cells treated 
with the virus alone and cells treated with the virus and GCV 50 µg/ml (p=0.037; unpaired t-
test; n=3) (Figure 11E). 
Also in GBM5 cells the combined treatment increased the fraction affected at each time 
point compared to the fraction affected with the virus alone (Figure 11F). Significant 
differences have been calculated between each condition at each time point examined (at 
day 3 BoHV-4TKdsRED-BoHV-4TKdsRED+GCV 10 µg/ml p=0.006, BoHV-4TKdsRED-BoHV-
4TKdsRED+GCV 50 µg/ml p=0.0006, BoHV-4TKdsRED-BoHV-4TKdsRED+GCV 100 µg/ml 
p=0.0002; at day 6 BoHV-4TKdsRED-BoHV-4TKdsRED+GCV 10 µg/ml p=0.001, BoHV-
4TKdsRED-BoHV-4TKdsRED+GCV 50 µg/ml p=0.0001, BoHV-4TKdsRED-BoHV-4TKdsRED+GCV 
 100 µg/ml p<0.0001; at day 9 BoHV
BoHV-4TKdsRED-BoHV-4TKdsRED+GCV 50 µg/ml p<0.0001, BoHV
4TKdsRED+GCV 100 µg/ml p<0.0001; n=6
Figure 11. Fraction affected of GBM2 (A, D), GBM4 (B, E) and GBM5 (C, F) at 3, 6 and 9 days after 
treatment with BoHV-4TKdsRED (BoHV) at MOI 0.5 and/or GCV 10, 50 or 100 µg/ml (GCV 10, GCV 50, 
GCV 100). (*p<0.05; ** p<0.001; mean ± SD)
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). 
 
-4TKdsRED-BoHV-
 
 
 5.2.5 BoHV-4TKdsRED 
To understand the killing mechanism of BoHV
with GBM2 cells was performed. GBM2 cells were infected with mock or BoHV
MOI 1 and 24 hours later treated with GCV 50 µg/ml or with PBS as a control for 24 hours 
before protein extraction. Nestin, Sox2 and GFAP expression have been checked to verify 
any possible variation after infection and/or GCV treatment. A very slight decrease in Nestin 
expression has been observed after BoHV
treatment seems to interfere with other markers expression. Two autophagy markers were 
tested: p62, an ubiquitin
expression decreases under autophagy due to protein degradation 
Moscat et al, 2012); LC3 (microtubule
for autophagosome formation 
cytoplasmic, and LC3-II, associated with the autophagosome membrane and increased 
during autophagosome formation 
Neither considered markers seem to be aff
Figure 12. Western Blots performed on GBM2 treated or untreated cells with BoHV
(BoHV) for 48 hours and GCV 50µg/ml for 24 hours. In the right panel α
after stripping. 
 
To further understand the effect of BoHV
GBM2 and GBM5 cells were plated and treated as already described and with Rapamycin 1 
µM, an autophagy inducer. Proteins were extracted in a wide
cells an LC3-II expression increase was seen in cells treated with GCV for 24 hours and in cells 
treated with BoHV-4TKdsRED for 72 hours plus GCV for 48 hours, but p62 expression was 
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Infection Effect In GSCs Cultures: Autophagy
-4TKdsRED in GSCs, a preliminary experiment 
-4TKdsRED+GCV treatment, while any other 
-binding protein involved in many cellular processes, which 
-associated protein light chain 3), an essential protein 
(Tanida et al, 2004). LC3 exists in two isoforms: LC3
(Kabeya et al, 2000). 
ected by any treatment (Figure12
-tubulin was not detec
-4TKdsRED and/or GCV on GSCs, 5*10
r range of time points. In GBM2 
 
-4TKdsRED at 
(Bjorkoy et al, 2006; 
-I, 
). 
 
-4TKdsRED 
table 
5 cells/well 
 not decreased. This could be a signal of 
complete activation of autophagy within the time points considered (Figure 1
In GBM5 cells the increase of LC3
hours and in cells treated with BoHV
a decrease of p62 expression. Also in this case it is possible to presume an initial 
autophagosome formation within the t
Figure 13. Western Blots performed on GBM2 (A) and GBM5 (B) treated or untreated cells with 
BoHV-4TKdsRED MOI 1 (BoHV), GCV 50 µg/ml (GCV), Rapamycin 1 µM (RAP) and DMSO.
 
5.2.6 BoHV-4TKdsRED 
The possible role of BoHV-
GBM2 and GBM5 cells were plated at a density of 2*10
with mock or BoHV-4TKdsRED MOI 1 or with Paclitaxel 100
24 hours cells were treated or not with GCV 50 µg/ml. After preliminary experiments, cells 
were analyzed 72 hours after BoHV
FACScaliburTM. In both GSCs cultures was detected a shift in the Annexin V fluorescence 
peak, compared to the unlabeled control, also in cells mock treated. This made it impossible 
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autophagosome formation, not sustained with a 
-II expression appeared in cells treated with GCV for 48 
-4TKdsRED for 72 hours plus GCV for 48 hours, without 
ime points considered (Figure 13
Infection Effect In GSCs Cultures: Apoptosis
4TKdsRED in apoptosis activation in GSCs has been investigated. 
4cells/well, the day after infected 
 nM, an apoptosis inducer. After 
-4TKdsRED infection for AnnexinV/PI fluorescence on BD 
3A). 
B). 
 
 
 
 
 to correctly determine fluorescence changes and so whether apoptosis is activated or
after treatments (Figure 14
Figure 14. Annexin V fluorescence on GBM2 cells 
µg/ml, D BoHV-4TKdsRED+GCV, E Paclitaxel 100 nM, F DMSO) and GBM5 cells (G MOCK, H BoHV
4TKdsRED MOI 1, I GCV 50 µg/ml, L BoHV
line: fluorescence of unlabeled contro
 
To verify whether this shift is linked to some peculiar cell characteristics, the same 
experiment with FBS5 cells has been performed. In this case it was possible to discriminate 
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-4TKdsRED+GCV, M Paclitaxel 100 nM, N DMSO). Green 
l; Purple: fluorescence of sample. 
 not 
 
 
-
 the negative peak from the positive one 
an apoptosis induction after BoHV
(Figure 15). 
 
Figure 15. Annexin V fluorescence on FBS5 cells (A MOCK, B BoHV
D BoHV-4TKdsRED+GCV, E Paclitaxel 100 nM, F DMSO).  Green line: fluorescence of unlabeled 
control; Purple: fluorescence of sample.
 
5.2.7 BoHV-4TKdsRED 
In order to verify whether BoHV
were seeded and the day after infected at MOI 0.2 with BoHV
2002), which allows a better visualization of reporter protein expressio
monitored and after 7 days where dissociated and plated at clonogenic density (1 cell/well). 
Cell were monitored until spheres formation. Five spheres have been identified. BoHV
4EGFPΔTK is able to infect self
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-4TKdsRED infection and after the combined treatment 
-4TKdsRED MOI 1, C GCV 50 µg/ml, 
 
Infection Of Self-Renewing Spheres 
-4 is able to infect self-renewing cells, 2*10
-4EGFPΔTK 
-renewing cells without causing cytopathic effect (Figure 1
 
4 GBM5 cells 
(Donofrio et al, 
n. Cells were 
-
6). 
 Figure 16. (A, B) GBM5 cells 6 days after BoHV
clonogenic density (1 cell/well). 10X; scale bar 200 µM.
 
 Spheres were mechanically dissociated and the infection was monitored through EGFP 
expression until 60 days after infection. Also in sphere
observed without cytopathic effects (Figure 1
Figure 17. (A-H) GBM5 spher
infection. 10X; scale bar 200 µM.
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-derived cultures EGFP expression was 
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es after mechanical dissociation; (I-R) GBM5 spheres 60 days after 
 
 
 
 The same experiment was performed with GBM2 cells, but in this case CPE was seen within 
the first 7 days of infection and no spheres were obtained after di
Figure 18. (A, B) GBM2 cells 6 days after BoHV
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6. DISCUSSION 
GBM is the most malignant and most frequent primary brain tumor in adults and it is still 
incurable, despite great progresses in today therapies (Stupp et al, 2009). In recent years the 
resistance of this tumor to therapies has been ascribed to the existence of some cells in the 
tumor mass with stem characteristics (Singh et al, 2003; Galli et al, 2004; Bao et al, 2006). 
Glioma Stem Cells are a low replicating, chemo- and radio-resistant subpopulation of cancer 
cells, so the goal of GBM therapies is the specific targeting of these cells (Chen et al, 2012). 
In order to selectively target GSCs novel therapeutic strategies have been studied and, 
among these, Gene Therapy using viral vectors can be a promising approach (Dey et al, 
2010). In the present study a BoHV-4-based vector engineered to express HSV-1 TK and the 
Red Fluorescent Protein as a reporter gene has been used. The presence of HSV-1 TK enables 
the vector to convert the prodrug GCV in a toxic metabolite in infected cells. This vector has 
already demonstrated its interesting role in infecting and killing immortalized glioma cell 
lines of different species and a primary human GBM culture (Redaelli et al, 2012). In the 
present study it has been used for the first time against GSCs cultures. 
Following published protocols(Wakimoto et al, 2009), GSCs cultures (GBM2, GBM4 and 
GBM5) were established from fresh human glioblastoma samples. From the same 
specimens, primary adherent cultures (FBS2, FBS4 and FBS5) were also obtained. The stem 
characteristics of our GSCs was verified through self-renewal assays and stem markers 
expression. Our GSCs cultures demonstrated different percentages of sphere-forming cells, 
when plated at clonogenic density. The cell growth of our culture has been studied and GSCs 
showed a gradual growth, whether serum-cultured cells, in particular FBS4 and FBS5, have a 
faster growth than their stem counterparts. This is in line with data reported in literature 
about the low replication rate of GSCs (Bao et al, 2006). 
The Bovine Herpesvirus vector BoHV-4TKdsRED is able to efficiently infect GSCs and serum-
cultured cells; it is able to slightly replicate in GBM2, GBM4, FBS2 and FBS4 cells within 72 
hours. In GBM5 cells viral replication was slower and in FBS5 cells, even after 144 hours of 
infection the viral titer didn’t get over the initial input; this probably because cells died 
before the virus completed the replication cycle. The viral replication was not high in GSCs, 
probably due to the slow replication rate of the cells. Indeed, the virus uses the cell 
machinery to replicate itself and so it is dependent on the mitotic activity of the infected 
cells (Capocefalo et al, 2009). 
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Despite its low replication rate, BoHV-4TKdsRED performs a cytopathic effect and kills GSCs 
and FBS cells. The fraction affected after 9 days in GSCs varied from 67% to 87%, with GBM5 
cells more resistant to infection than other cultures. FBS cells resulted more sensitive to 
infection than GSCs, in particular FBS2 and FBS4 cells were almost completely killed after 9 
days. The different killing ability of BoHV-4TKdsRED in cells derived from different patients 
stresses the high heterogeneity of GBM. 
The killing ability of BoHV-4TKdsRED in GSCs was lower than the one showed by HSV-1 wild 
type. Of course, it is important to keep in mind that HSV-1 wild type has a high 
neuropathogenicity, which is not the case of BoHV-4, and that the use of wild type HSV-1 is 
impossible in patients because it causes lethal encephalitis. Conversely, BoHV-4 resulted no 
neuropathogenic in animal models and would be a safe viral vector (Donofrio et al, 2006).  
Experiments of Suicide Gene therapy highlighted a time- and dose-dependent increase of 
BoHV-4TKdsRED with a combined used of different doses of the prodrug GCV in GSCs. Also in 
this case GBM5 cells resulted more resistant to treatments. This resistance could derive from 
the higher percentage of self-renewing cells in GBM5 culture. 
The further question was about how BoHV-4TKdsRED exerts its cytopathic effect. Autophagy 
is a mechanism involved in many cell functions and can have a pro-survival or a pro-death 
role (Ouyang et al, 2012). Its role in cancer is still not completely understood and an 
autophagy downregulation seems to be correlated with tumor progression in GBM (Huang 
et al, 2010). BoHV-4TKdsRED infection alone is not able to induce autophagy, but the 
combined treatment with GCV induces a first autophagosome formation after 48 hours, as 
detected with LC3-II increased expression in Western Blots, in GBM2 and GBM5 cells. These 
results were not sustained by a p62 expression decrease, suggesting an incomplete 
autophagy activation. Whether this incomplete activation is due to a downregulated ability 
of GSCs to perform autophagy or to a non sufficient exposition time of the cells to the 
treatments, is a point that is still unclarified. 
Apoptosis is the most known type of Programmed Cell Death and is downregulated in cancer 
cells (Krakstad et al, 2010). BoHV-4TKdsRED resulted able to induce apoptosis in 
immortalized glioma cell lines and in a primary human GBM culture, in particular when used 
in combination with GCV (Redaelli et al, 2012). The apoptosis activation was investigated 
also in GSCs through Annexin V/PI FACS analysis. Annexin V fluorescence was not reliable in 
GBM2 and GBM5 cells. So it was not possible to determine whether the virus alone or the 
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combined treatment induce apoptosis in GSCs. The same result was not observed in FBS5 
cells, where an increase in Annexin V fluorescence was detected in cells treated with BoHV-
4TKdsRED and with the combined treatment. Probably the unusual Annexin V fluorescence 
in GSCs is due to an unspecific binding of the die. Annexin V binds to Phosphatidylserine, 
which is exposed on the cell membrane during apoptosis (Demchenko 2012). However, this 
method has some pitfalls and can determine false positives (Demchenko 2013). The reason 
of the Annexin V fluorescence peak shift detected in our GSCs is still unknown. 
The real goal of Gene Therapy is the selective killing of GSCs, in particular of self-renewing 
cells. Another BoHV-4-derived vector, BoHV-4EGFPΔTK was used to verify the infection of 
self-renewing cells. BoHV-4EGFPΔTK has the same characteristics of BoHV-4TKdsRED, except 
for the lack of HSV-1 TK and the EGFP in place of RFP as reporter gene. EGFP allows a better 
visualization of infected cells than RFP. The self-renewal assay performed after GBM5 
infection with BoHV-4EGFPΔTK showed that the vector is able to infect self-renewing cells, 
but didn’t exert a cytopathic effect in these cells. Even 60 days after infection and after 
mechanical dissociation of the spheres, cells appeared healthy. 
For the first time this study demonstrated the ability of BoHV-4TKdsRED to infect human 
GSCs. From the results obtained so far, we can consider BoHV-4TKdsRED a good candidate 
for Gene Therapy of GSCs, but further analysis should be performed to verify the killing 
mechanisms involved. Moreover, further studies are necessary to assess whether the 
combined treatment of BoHV-4TKdsRED and GCV is able to kill also self-renewing and not 
only the rapidly-proliferating compartment of GSCs.  
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